Free Trial

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Here's Why

Jyong Biotech logo with Manufacturing background

Key Points

  • Jyong Biotech's shares opened at $54.00 after previously closing at $51.82, reflecting significant investor interest as the stock last traded at $56.00.
  • Wall Street analysts upgraded Jyong Biotech to a "hold" rating, which may influence future market performance and investor decisions.
  • The company's 50-day moving average is currently at $34.25, indicating a positive upward trend in stock performance.
  • MarketBeat previews the top five stocks to own by October 1st.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $51.82, but opened at $54.00. Jyong Biotech shares last traded at $56.00, with a volume of 4,582 shares traded.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a report on Monday, June 30th.

Get Our Latest Stock Report on MENS

Jyong Biotech Stock Performance

The company has a 50-day moving average of $34.25.

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jyong Biotech Right Now?

Before you consider Jyong Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.

While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.